Chapel Hill, NC, United States of America

Barbara Calamini

This inventor holds 1 USPTO granted patent. Top assignee: Northwestern University. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barbara Calamini. Retrieved from https://idiyas.com/inventor/barbara-calamini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Barbara Calamini: Innovator in HSF-1 Modulation

Introduction

Barbara Calamini is a distinguished inventor based in Chapel Hill, NC (US). She has made significant contributions to the field of molecular biology, particularly in the modulation of heat shock factor 1 (HSF-1). Her innovative approach has the potential to impact various biological processes and therapeutic strategies.

Latest Patents

Barbara Calamini holds a patent for a method of modulating HSF-1 activity. The patent, titled "Method of Modulating HSF-1," focuses on modifying the acetylation of the DNA binding domain of HSF-1. This invention represents a crucial advancement in understanding and manipulating cellular stress responses.

Career Highlights

Calamini is affiliated with Northwestern University, where she conducts her research and develops her inventions. Her work has garnered attention for its potential applications in treating diseases related to protein misfolding and cellular stress.

Collaborations

Throughout her career, Barbara has collaborated with notable researchers, including Julius Anckar and Richard I. Morimoto. These partnerships have enriched her research and expanded the impact of her innovations.

Conclusion

Barbara Calamini is a pioneering inventor whose work on HSF-1 modulation exemplifies the intersection of innovation and scientific research. Her contributions continue to advance our understanding of cellular mechanisms and hold promise for future therapeutic developments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…